Learn, Analyse & Invest
only with

+91

Download Orca

To access realtime data for Reliance Industries Ltd, and use advance features for tradingRegisterorLogin to Orca.

Natco Pharma Ltd.

Natco Pharma

₹ 0.00

0.00 (0.00)%

NSE

BSE

Healthcare

Small-cap - With a market cap of ₹170.82 Cr.

EX-Date	Purpose
17 06 2021	Interim Dividend & Audited Results
12 08 2021	Quarterly Results & Interim Dividend
11 11 2021	Quarterly Results & Interim Dividend
14 02 2022	Third Interim Dividend & Quarterly Results
30 05 2022	Audited Results
09 08 2022	Interim Dividend & Quarterly Results
10 11 2022	Quarterly Results & Second Interim Dividend
09 02 2023	Quarterly Results & Interim Dividend
08 03 2023	Buy Back of Shares
29 05 2023	Audited Results
09 08 2023	Quarterly Results & Interim Dividend
14 11 2023	Quarterly Results & Interim Dividend
14 02 2024	Interim Dividend & Quarterly Results
12 11 2024	Quarterly Results & Interim Dividend
12 02 2025	Quarterly Results & Interim Dividend
28 05 2025	Audited Results

News

01-MAR-2023

Natco Pharma launches Pomalidomide Capsules in Canada

It is the second most common form of blood cancer in Canada with about 8,000 Canadians living with myeloma

09:23 AM

04-OCT-2022

Natco Pharma launches Chlorantraniliprole combination Agro Products in India

Syngenta markets these combination products under brand names Voliam Flexi and Ampligo

11:30 AM

09-APR-2024

Natco Pharma gets warning letter from USFDA for Telangana plant

A warning letter is issued when the US health regulator finds that a manufacturer has significantly violated its regulations

05:16 PM

09-NOV-2022

Natco Pharma launches first generic version of Pomalyst Capsules in Australian market

Pomalyst registered sales of $35.6 million in the Australian market for the year ending March 31, 2022 as per industry sales data

11:39 AM

10-FEB-2025

Natco Pharma receives approval for ANDA for Bosentan tablets

It has sole First-to-File status for the product and is eligible for a 180-day exclusivity at the time of launch

11:30 AM

10-MAR-2023

Natco Pharma launches additional strengths for generic version of Revlimid in USA

With this launch the companies made available all the strengths of lenalidomide in the US market

09:20 AM

13-FEB-2023

Natco Pharma files ANDA for generic version of Olaparib Tablets

Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic and prostrate cancer

12:49 PM

13-JUN-2025

USFDA concludes inspection at Natco Pharma’s Hyderabad API manufacturing plant

On conclusion of the inspection, the Company received 1 observation in the Form 483

04:44 PM

16-JUN-2023

Natco Pharma gets EIR from USFDA for Andhra Pradesh manufacturing facility

Earlier, USFDA had conducted inspection at the said manufacturing facility from January 30, 2023 to February 03, 2023

11:38 AM

16-JUN-2023

Natco Pharma gets final nod for Tipiracil Hydrochloride and Tifluridine Tablets

Lonsurf is indicated primarily for the treatment of colorectal cancer

09:30 AM

17-JAN-2024

Natco Pharma invests around $2 million in Cellogen Therapeutics

Cellogen is primarily involved in two R&D programs involving cell and gene therapy solutions

05:35 PM

18-AUG-2022

Natco Pharma gets USFDA’s tentative approval for Trabectedin for Injection

Yondelis generated annual sales of $49.7 million for the twelve months ending June 2022 in the US market

09:09 AM

20-APR-2023

Natco Pharma to incorporate subsidiary company in Indonesia

The balance stake of 49% will be held by PT. Mitra Medis Exim

12:13 PM

20-JUN-2025

USFDA concludes inspection at Natco Pharma’s Kothur pharma division

On conclusion of the inspection, the Company received seven observations in the Form-483

10:20 AM

20-SEP-2022

Natco Pharma gets CTPR launch approval from Delhi High Court

CTPR technical is formulated into broad-spectrum insecticides used across wide range of crops for pest management

09:58 AM

24-JUL-2025

Natco Pharma gets nod to incorporate wholly owned subsidiary in South Africa

The objective of incorporation of subsidiary is to enter new geographies for growth and increased profitability.

11:00 AM

25-JUL-2025

USFDA issues EIR to Natco Pharma’s Hyderabad API division

USFDA had conducted an inspection at said facility from June 9, 2025 to June 13, 2025

04:30 PM

26-JUL-2023

Natco Pharma files ANDA for generic version of Erdafitinib Tablets

Erdafitinib Tablets are marketed in the United States by Janssen Biotech under brand Balversa

02:50 PM

26-SEP-2022

Natco Pharma launches Chlorantraniliprole 18.5% SC under Brand Name ’NATGEN’

The company estimates the current market size of CTPR containing products in India to be over Rs 2000 crore.

09:09 AM

30-JAN-2025

Natco Pharma gets ANDA approval for Everolimus tablets for oral suspension

NATCO’s marketing partner for the ANDA, Breckenridge Pharmaceutical, Inc plans to launch the product immediately in the US market

09:59 AM

31-AUG-2023

Natco Pharma makes strategic investment in ISCA Inc

Cost of acquisition is $2 million

10:23 AM